Mode of action
- Switches on GIP receptors
- Switches on GLP-1 receptors
- Together they help control appetite, energy intake and blood sugar

Dual GIP and GLP-1 agonist for weight loss and weight maintenance.

Weight loss and long-term weight maintenance in eligible patients. Some products are approved for type 2 diabetes.
Injection under the skin (subcutaneous), once a week. In trials: start at 2.5 mg and add 2.5 mg every 4 weeks.
| Receptor | What it does | |
|---|---|---|
| GLP-1 | Lowers appetite, slows stomach emptying, helps insulin release | Yes |
| GIP | Helps insulin release and appetite and energy control | Yes |
| Glucagon | Being studied for raising energy use | No |
Source: SURMOUNT-1 (ADA 2022; Lilly release, April 2022); 176-week results reported by Healio, 2024. Average % of body weight lost at 72 weeks.
About 80% had at least one side effect on tirzepatide (placebo: 72%); 4–7% stopped because of side effects. Common stomach effects in trials: nausea, vomiting, diarrhea and constipation. Doctors also check for dehydration, gallbladder disease and pancreatitis.
Source: ZEPBOUND prescribing information (DailyMed); SURMOUNT-1 trial. The label on every PeptoPlus unit hides a one-time code under a scratch layer, with a QR beside it. Scan it to check that the code was issued by PeptoPlus.